You are viewing: South Korea Recombinant Proteins Market analysis
Part of: Recombinant Proteins Market (Global)

The South Korea Recombinant Proteins Market was valued at $14 Million in 2023 and projected to reach to $18.8 Million by 2028, representing a compound annual growth rate of 6.0%. South Korea's recombinant proteins market is poised for steady growth through 2028, supported by the country's advanced biotechnology ecosystem and increasing investment in biopharmaceutical research and development.

South Korea Recombinant Proteins Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

South Korea Recombinant Proteins Market Trends and Insights

  • South Korea's advanced biotechnology infrastructure and strong pharmaceutical sector position the country as a key player in recombinant protein development and commercialization across Asia Pacific.
  • The market in South Korea is driven by increasing demand for biologics, rising prevalence of chronic diseases, and significant investment in research and development by both government and private entities. South Korea's healthcare system continues to prioritize innovative therapeutic solutions, creating favorable conditions for recombinant protein adoption.
  • South Korea's regulatory framework supports expedited approval pathways for biopharmaceuticals, enabling faster market entry for novel recombinant protein therapies.
  • Between 2023 and 2028, South Korea is expected to see sustained growth fueled by expanding manufacturing capabilities, growing clinical applications, and increasing healthcare expenditure..

Key Market Statistics

  • CAGR (2023-2028) 6.0% CAGR
  • Market Size, 2023 ~USD 14 Million
  • Forecast, 2028 ~USD 18.8 Million
  • Country South Korea

South Korea Recombinant Proteins Market Overview

Market Valuation Growth :

South Korea's recombinant proteins market reached $14.0 million in 2023 and is expected to expand to $18.8 million by 2028, driven by increasing demand for biopharmaceuticals and therapeutic proteins in the region.

Biotechnology Infrastructure :

South Korea possesses advanced biotechnology infrastructure and research capabilities, positioning it as a regional hub for recombinant protein development, manufacturing, and commercialization across Asia Pacific.

Pharmaceutical Sector Strength :

The country's robust pharmaceutical sector and government support for biotech innovation create favorable conditions for recombinant protein market expansion and investment in protein-based therapeutics.

Regional Market Position :

South Korea serves as a key player in Asia Pacific's recombinant proteins landscape, with growing adoption of biologics and increasing healthcare expenditure supporting market growth at a 6.0% CAGR through 2028.

South Korea Recombinant Proteins Market Dynamics

  • The market's 6.0% CAGR reflects growing demand for protein-based therapeutics, including monoclonal antibodies, growth factors, and recombinant enzymes used in treating chronic diseases and cancer. Government initiatives promoting biotech innovation, coupled with South Korea's skilled workforce and manufacturing capabilities, will drive market expansion.
  • Rising healthcare spending, aging population demographics, and increased adoption of biologics in clinical practice are expected to accelerate recombinant protein commercialization.
  • Strategic partnerships between domestic biotech firms and international pharmaceutical companies will further strengthen South Korea's position as a regional leader in recombinant protein development and production..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • South Korea's recombinant proteins market is valued at $14.0 million in 2023 with projected growth to $18.8 million by 2028.
    • South Korea demonstrates a 6.0% CAGR, reflecting steady expansion driven by biotechnology advancement and healthcare innovation.
    • South Korea's robust regulatory environment and manufacturing infrastructure support rapid commercialization of recombinant protein therapies.
    • South Korea's growing chronic disease burden and increased R&D investment are key catalysts for market expansion through 2028.

    Recombinant Proteins Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment INTERFERONS (IFNS) (Type)
    Forecast Period 2023-2028
    Growth Rate CAGR of 7.2% from 2023 to 2028
    Largest Segment PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 2.26 (2023)
    Revenue Forecast (Billions) ~USD 3.2 (2028)
    Segments Covered Product, Type, Application, Host Cell, End User

    South Korea Recombinant Proteins Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Other Recombinant Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins

    By Type

    • Academic Research
    • Biologics
    • Biotechnology Research
    • Cell & Gene Therapy
    • Interferons (Ifns)
    • Interleukins (Ils)
    • Other Growth Factors & Chemokines
    • Vaccines

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Discovery & Development
    • Other Applications
    • Research

    By Host Cell

    • Bacterial Cells
    • Insect Cells
    • Mammalian Systems
    • Other Cell Hosts
    • Other Host Cells
    • Yeast & Fungi

    By End User

    • Academic Research Institutes
    • Biotechnology Companies
    • Contract Research Organizations
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    Target Audience

    • Biopharmaceutical Companies : South Korean and international biotech firms need market-specific data to assess market potential, identify local partnerships, and develop commercialization strategies for recombinant protein products in Korea.
    • Healthcare Investors & Venture Capitalists : Investment firms targeting South Korea's biotech sector require detailed market sizing and growth forecasts to evaluate funding opportunities in recombinant protein development and manufacturing ventures.
    • Contract Manufacturing Organizations (CMOs) : CMOs and contract research organizations need South Korea market intelligence to understand demand for recombinant protein manufacturing services and identify expansion opportunities in the region.
    • Pharmaceutical Regulatory Bodies : South Korean regulatory agencies and healthcare authorities require market data to inform policy decisions, biotech incentive programs, and strategic planning for the recombinant proteins sector.
    • Market Research & Consulting Firms : Research organizations and consultants need country-specific market data to support client advisory services, competitive analysis, and strategic recommendations for stakeholders in South Korea's biotech industry.

    Reasons to Buy this Report

    • Market-Specific Sizing & Forecasts : Access precise valuation data for South Korea's recombinant proteins market with detailed 2023-2028 projections, enabling accurate financial planning and investment decisions tailored to this specific regional market.
    • Competitive Landscape Intelligence : Understand South Korea's unique biotechnology ecosystem, key players, manufacturing capabilities, and regulatory environment to identify partnership opportunities and competitive positioning within the region.
    • Growth Driver Analysis : Gain insights into South Korea-specific factors driving market expansion, including government biotech initiatives, healthcare spending trends, and adoption of protein-based therapeutics in clinical practice.
    • Regional Strategic Planning : Develop targeted market entry and expansion strategies for South Korea by leveraging country-specific data on demand patterns, distribution channels, and emerging opportunities in the recombinant proteins sector.
    • Investment & Funding Decisions : Make informed investment decisions regarding South Korean biotech ventures, manufacturing facilities, and R&D collaborations with comprehensive market intelligence and growth trajectory analysis.

    Frequently asked questions

    What is the current market size of recombinant proteins in South Korea?

    South Korea's recombinant proteins market was valued at $14.0 million in 2023 and is expected to reach $18.8 million by 2028.

    What is the projected growth rate for South Korea's recombinant proteins market?

    South Korea's recombinant proteins market is projected to grow at a compound annual growth rate (CAGR) of 6.0% from 2023 to 2028.

    What factors are driving growth in South Korea's recombinant proteins market?

    South Korea's market growth is driven by advanced biotechnology infrastructure, rising chronic disease prevalence, strong government and private R&D investment, and supportive regulatory frameworks for biopharmaceuticals.

    How does South Korea's recombinant proteins market compare to other Asia Pacific countries?

    South Korea maintains a competitive position in Asia Pacific due to its advanced manufacturing capabilities, skilled workforce, and innovation-focused healthcare system supporting recombinant protein development.

    What regulatory advantages does South Korea offer for recombinant protein companies?

    South Korea's regulatory framework includes expedited approval pathways for biopharmaceuticals, enabling faster market entry and commercialization of novel recombinant protein therapies.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the recombinant proteins market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive technical, market-oriented, and commercial study of the recombinant proteins market. The secondary sources used for this study include The Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), American Medical Association (AMA), Recombinant Antibody Network (RAN) National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Department of Agriculture (USDA), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), Institute for Molecular Medicine, Annual Reports, SEC Filings, Press Releases, Company Websites, Investor Presentations, Magazines, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global recombinant proteins market, which was validated through primary research.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Recombinant proteins Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the recombinant proteins market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The major players in the industry and market have been identified through extensive primary and secondary research.
    • The revenues generated from the recombinant proteins service business of players operating in the market have been determined through secondary research and primary analysis.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

    Global Recombinant proteins Market Size :Bottom-Up Approach

    Recombinant proteins Market Size, and Share

    To know about the assumptions considered for the study, Request for Free Sample Report

    Top-Down Approach

    Recombinant proteins Market Size, and Share

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    • Recombinant proteins are manipulated forms of proteins that are generated by recombinant DNA technology which modifies the gene sequences. These are formed by transfecting foreign genes into a host cell. They are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses.

    Key Stakeholders

    • Pharmaceutical and biotechnology companies
    • Life sciences companies
    • Academic research institutes
    • Government institutes
    • Private research firms
    • Contract Research Organizations (CROs)
    • Third-party suppliers, direct suppliers, distributors, and channel partners
    • Venture capitalists and investors
    • Market research and consulting firms

    Report Objectives

    • To define, describe, and forecast the recombinant proteins market by product, application, host cell, end user, and region.
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall recombinant proteins market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa.
    • To profile the key players and analyze their market shares and core competencies2
    • To track and analyze competitive developments, such as acquisitions, product launches, expansions, agreements, partnerships and research & development activities.
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

    Available Customizations

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

    Product Analysis

    • Product matrix, which provides a detailed comparison of the product portfolio of each company in the recombinant proteins Market

    Get the Full Recombinant Proteins Market Report

    Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status